Response to Phenylketonuria to Tetrahydrobiopterin (BH4)
Latest Information Update: 05 Nov 2021
At a glance
- Drugs Sapropterin (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- 08 Feb 2021 Status changed from recruiting to discontinued, as the FDA has approved Kuvan (BH4) as a therapeutic agent for phenylketonuria.
- 28 Feb 2017 New trial record